CSL (OTCMKTS:CSLLY) Shares Down 6% – Time to Sell?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) traded down 6% during mid-day trading on Tuesday . The company traded as low as $60.50 and last traded at $60.5795. 20,155 shares were traded during mid-day trading, a decline of 86% from the average session volume of 143,293 shares. The stock had previously closed at $64.4687.

Analyst Upgrades and Downgrades

CSLLY has been the topic of several recent research reports. Royal Bank Of Canada raised shares of CSL from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. Finally, Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

CSL Trading Down 6.5%

The company’s 50-day moving average is $60.08 and its 200-day moving average is $66.00. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.